Biodrugs

Papers
(The H4-Index of Biodrugs is 23. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Therapeutic siRNA: State-of-the-Art and Future Perspectives161
Engineered Bacteriophage Therapeutics: Rationale, Challenges and Future80
Antisense Oligonucleotide Therapy: From Design to the Huntington Disease Clinic63
Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer55
Immunogenicity Challenges Associated with Subcutaneous Delivery of Therapeutic Proteins55
Dengue Vaccines: An Update53
Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease46
Teserpaturev/G47Δ: First Approval43
European Stakeholder Learnings Regarding Biosimilars: Part I—Improving Biosimilar Understanding and Adoption42
Administration of CD4+CD25highCD127−FoxP3+ Regulatory T Cells for Relapsing-Remitting Multiple Sclerosis: A Phase 1 Study41
Clinical Development of New Antibody–Drug Conjugates in Breast Cancer: To Infinity and Beyond40
CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success38
Anti-Drug Antibody Formation Against Biologic Agents in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis37
RNA Targeting and Gene Editing Strategies for Transthyretin Amyloidosis33
Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities31
Focused Update on AAV-Based Gene Therapy Clinical Trials for Inherited Retinal Degeneration30
Recent Achievements and Challenges in Prolonging the Serum Half-Lives of Therapeutic IgG Antibodies Through Fc Engineering29
Novel Targeted Biological Agents for the Treatment of Atopic Dermatitis27
SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin27
Anti-VEGF and Other Novel Therapies for Neovascular Age-Related Macular Degeneration: An Update27
Tumor in the Crossfire: Inhibiting TGF-β to Enhance Cancer Immunotherapy26
Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants26
Safety of Intravitreal Gene Therapy for Treatment of Subjects with Leber Hereditary Optic Neuropathy due to Mutations in the Mitochondrial ND4 Gene: The REVEAL Study25
Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale23
Cryopreservation of NK and T Cells Without DMSO for Adoptive Cell-Based Immunotherapy23
Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies23
Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial23
0.8347430229187